Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia
Pharmacoepidemiology and Drug Safety2011Vol. 20(9), pp. 903–913
Citations Over TimeTop 10% of 2011 papers
Abstract
Of antidepressants studied, only mirtazapine had a statistically significantly greater SD/VA risk versus paroxetine. However, baseline differences between these users suggest that this finding may be attributable to residual confounding. Eleven other antidepressants had SD/VA risks no greater than that of paroxetine, thereby providing reassurance regarding the comparative cardiovascular safety of antidepressants.
Related Papers
- → Can we recommend mirtazapine and bupropion for patients at risk for bleeding?: A systematic review and meta-analysis(2017)32 cited
- → Mirtazapine and Bupropion Combined Treatment in Treatment-resistant Depression(2009)1 cited
- → Experiences with Doxepin and Trazodone in the Therapy with Outpatients Suffering from Depression(1984)5 cited
- Comparison study of efficacy and safety of mirtazapine and trazodone added to hypnotics-resistant insomnia(2007)
- Effect of Mirtazapine in treatment of depression(2011)